Home

Exact Sciences Corporation - Common Stock (EXAS)

44.91
+3.17 (7.59%)
NASDAQ · Last Trade: Aug 13th, 6:26 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Via StockStory · August 13, 2025
1 Small-Cap Stock to Own for Decades and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Via StockStory · August 13, 2025
Micron To Rally More Than 49%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · August 12, 2025
Earnings Scheduled For August 6, 2025benzinga.com
Via Benzinga · August 6, 2025
An Overview of Exact Sciences's Earningsbenzinga.com
Via Benzinga · August 5, 2025
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q2 CY2025, with sales up 16% year on year to $811.1 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 84.9% above analysts’ consensus estimates.
Via StockStory · August 12, 2025
3 Out-of-Favor Stocks We Steer Clear Of
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Via StockStory · August 12, 2025
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com
The rock-star money manager is making the most of sell-offs in some of her stocks.
Via The Motley Fool · August 11, 2025
Beyond The Numbers: 7 Analysts Discuss Exact Sciences Stockbenzinga.com
Via Benzinga · August 11, 2025
Top 3 Health Care Stocks That Are Preparing To Pump This Monthbenzinga.com
Via Benzinga · August 11, 2025
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analystbenzinga.com
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a major strategic move.
Via Benzinga · August 7, 2025
Discover the top movers in Thursday's pre-market session.chartmill.com
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · August 7, 2025
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 7, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 7, 2025
Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · August 7, 2025
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 16% year on year to $811.1 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts’ estimates. Its non-GAAP profit of $0.22 per share was significantly above analysts’ consensus estimates.
Via StockStory · August 6, 2025
Exact Sciences (EXAS) Q2 Revenue Up 16%fool.com
Via The Motley Fool · August 6, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · August 6, 2025
Stay updated with the stocks that are on the move in today's after-hours session.chartmill.com
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · August 6, 2025
How Exact Sciences Is Spending $775 Million To Dominate The Cancer-Screening Marketinvestors.com
The company is expanding its oncology efforts with a deal for a blood-based colorectal cancer screening test.
Via Investor's Business Daily · August 6, 2025
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here’s what to expect.
Via StockStory · August 4, 2025
3 Cash-Producing Stocks We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · July 28, 2025
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. 
Via StockStory · July 18, 2025
1 Healthcare Stock for Long-Term Investors and 2 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 7.8%. This drop is a far cry from the S&P 500’s 7.1% ascent.
Via StockStory · July 14, 2025
Forecasting The Future: 9 Analyst Projections For Exact Sciencesbenzinga.com
Via Benzinga · July 8, 2025